Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study

The authors declare no potential conflicts of interest. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15552. The raw data supporting the conclusions of this article will be made available by the authors. Further inquiries can be directed to the corresponding author. Data S1. Supporting Information. Figure S1. Changes in total cholesterol and uric acid when treatment with semaglutide compared to non-GLP-1RA from baseline to continuous clinical endpoints over time (T3 to T12). (A) Changes in total cholesterol. (B) Changes in uric acid. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.